Researchers at ChristianaCare’s Gene Editing Institute have demonstrated that turning off the NRF2 gene with CRISPR technology can make lung cancer cells responsive to chemotherapy again. By blocking this gene, the treatment restores how tumors…
Researchers at ChristianaCare’s Gene Editing Institute have demonstrated that turning off the NRF2 gene with CRISPR technology can make lung cancer cells responsive to chemotherapy again. By blocking this gene, the treatment restores how tumors…